Lymphoma Clinical Trials in New York

Showing 221-240 of 620 trials

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

NCT04488354

This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells

Relapsed/Refractory B-cell LymphomasDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)+9 more

Calibr, a division of Scripps Research36 participantsStarted Jan 2021

Duarte, California, United States • San Diego, California, United States • Chicago, Illinois, United States +5 more locations

TERMINATEDPhase 2< 1 mile

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

NCT04305444

Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma.

Relapsed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaDiffuse Large B Cell Lymphoma+2 more

Zhejiang DTRM Biopharma55 participantsStarted Apr 2020

Phoenix, Arizona, United States • New Haven, Connecticut, United States • Jacksonville, Florida, United States +5 more locations

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Lymphoma Trials in Other Cities

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

The In4M Study: Integrating 4 Methods to Assess Physical Function in Cancer Patients

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Other Conditions in New York